4.3 Reference Safety Information and IB Updates

Reference Safety Information and IB Updates

The Reference Safety Information (RSI) is the specific section of the Investigator's Brochure (typically located within the designated safety information) that serves as the legal and regulatory benchmark for determining whether a serious adverse reaction is "expected" or "unexpected."

Why the RSI is Vital for Expedited Safety Reporting

Under ICH E2A , expedited safety reporting is reserved for events meeting three concurrent criteria:

1. Serious: Results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, causes a congenital anomaly/birth defect, or is an important medical event.
2. Related (Adverse Reaction): A reasonable possibility exists that the investigational product caused the event.
3. Unexpected: The nature, severity, or frequency of the reaction is not consistent with the Reference Safety Information in the applicable version-controlled IB.

An event meeting seriousness, suspected relationship and unexpectedness criteria is a SUSAR. Under E2A, fatal/life-threatening unexpected suspected reactions are reported as soon as possible within seven calendar days after qualifying knowledge, with as complete a follow-up as possible within eight additional days. Other serious unexpected suspected reactions are reported as soon as possible within fifteen calendar days after minimum criteria are met. Follow-up information should be actively sought; a complete final hospital record is not a prerequisite to the initial report.

An expected serious reaction ordinarily does not qualify for individual SUSAR reporting, but the investigator still follows SAE reporting requirements and the sponsor evaluates cumulative information. A clinically important increase in an expected reaction rate or another important finding can require rapid communication under E2A. Do not assume that an expected classification makes information unimportant.

Annual review and version control

E6(R3) Appendix A calls for IB review at least annually and revision as necessary under sponsor procedures. Important new information may need communication to investigators, IRBs/IECs or authorities before a revised IB is available. The appropriate action depends on the finding; there is no universal requirement to use one named letter format. Preserve the applicable edition and history so earlier expectedness assessments and site decisions remain interpretable.

The CRA should trace version distribution, appropriate investigator/staff review, relevant ethics handling and any consent or protocol implications. A signed receipt is evidence of receipt, not proof that a new risk was incorporated into site practice. Ask whether affected staff understand what changes and whether the participant information needs timely updating.

Interpreting background safety information

A nonclinical finding can support targeted clinical surveillance without determining one universal schedule. For example, a sponsor may incorporate cardiac assessments when background information suggests a cardiac risk. The actual frequency, thresholds and responses belong in the authorised protocol and associated instructions. A CRA verifies those requirements and confirms investigator review of results; the CRA must not invent stopping rules from an IB summary.

The IB should provide balanced guidance, including limitations and relevant negative findings. Distinguish product-specific observations from a class effect, an anticipated risk from an established adverse reaction, and background scientific information from the designated RSI. A general list of possible risks cannot automatically make every serious reaction expected. Preserve the edition used for each assessment so historical decisions can be reconstructed.

For investigational devices, use the relevant instructions for use (IFU), product information and protocol. Check the approved model/configuration, intended use, handling precautions, required operator training and product traceability. Device terminology in the ECO does not mean FDA device classification rules are examination references. Clinical staff need the current instructions actually applicable to the device supplied, not a brochure for a different marketed model.

CRA Operational Responsibilities: Site-Level IB Management

When conducting monitoring visits, the CRA acts as the primary quality auditor ensuring that the Investigator Site File (ISF) reflects the current safety reality of the investigational product.

The CRA Monitoring Checklist for IB Updates

1. Version Reconciliation: Confirm that the active IB version in the ISF matches the master version documented in the Trial Master File (TMF). Confirm that obsolete versions are stamped "SUPERSEDED" and retained in historical files. Prior versions must never be thrown away or destroyed.
2. Training Documentation: Verify that the Principal Investigator and affected staff received and understood relevant updated information, with documentation appropriate to their roles.
3. IRB/IEC Compliance: Verify that the updated IB was submitted promptly to the site's IRB/IEC. Check for the evidence of required IRB/IEC submission and handling and ensure it is filed in the regulatory binder.
4. Informed Consent Form (ICF) Assessment: If the updated IB introduces new safety risks or alters the risk-benefit assessment, verify that the sponsor provided an updated model ICF. Check whether the site updated its local ICF, secured IRB approval, and re-consented all actively enrolled participants who remain exposed to trial interventions.

Official sources

Checked October 18, 2026: ICH E6(R3), Principles and Annex 1, ICH E9, ICH E9(R1), ICH E8(R1).